CURRENT ISSUE

In this month’s issue of ProVisions, we take a deep dive into the coverage and liability questions surrounding compound and off-label prescribing—a rapidly evolving area that’s generating more underwriting conversations by the day. We examine the surge in GLP-1 receptor agonist use, including how shifting prescribing patterns affect liability exposure and what defensible documentation looks like, as well as the growing use of ketamine for mental health and chronic pain management. As always, our underwriting, risk management, and claims teams are available to help you navigate these topics with your clients.

ProVisions is also available as a printed magazine. Sign up below to join the mailing list. Please specify the number of copies your office should receive in your message.